ArticleFrontiers in pharmacology2025
Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world safety profile of eravacycline compared with tigecycline, minocycline, and meropenem: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacovigilance analysis of central nervous system adverse events associated with sevoflurane and drug interactions: a disproportionality study based on the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced neuralgia is a common and significant adverse reaction. This study analyzed the United States food and drug administration adverse event reporting system (FAERS) database (2004-2024) to identify relevant drugs and potential mechanisms. Methods: We conducted an association analysis between drugs and neuralgia using the FAERS database. Disproportionality analysis methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM), were applied. Data from 2004 to 2024 were analyzed to identify drugs potentially associated with neuralgia. Results: Among the 103,678 reports of neuralgia-related adverse events, 60.29% involved female patients, and 30.40% were aged between 41 and 64 years. The most common underlying medical conditions were plasma cell myeloma (14.28%) and multiple sclerosis (10.65%). The analysis revealed significant associations between neuralgia and several classes of drugs, including chemotherapeutic agents, certain antibiotics, and immunosuppressants, potentially attributable to neurotoxicity, immune-mediated mechanisms, or metabolic disruptions. Notably, lenalidomide exhibited the strongest association with neuralgia, followed by sodium citrate. These findings underscore the importance of early recognition, safer prescribing strategies, and further investigation to mitigate neurotoxic risks. Conclusion: This study identifies key drugs, including chemotherapeutics, antibiotics, and immunosuppressants, associated with drug-induced neuralgia through FAERS data analysis, highlighting the need for early detection, safer prescribing practices, and further research into mitigating neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.